Calcimar (synthetic salmon calcitonin-solution for injection) - labelling changes to the product monograph due to an increased risk of cancer with long-term use

Sanofi-aventis Canada Inc. (Sanofi Canada), in collaboration with Health Canada, would like to inform you about important changes to the conditions of use for Calcimar® regarding an increased risk of malignancies with long term calcitonin use. Health Canada has evaluated information on the risk of malignancies from randomised controlled trials in patients with osteoporosis or osteoarthritis receiving calcitonin (salmon) nasal spray or an unlicensed oral calcitonin formulation. Patients treated with calcitonin in these trials had a low, but observable increased rate of malignancies compared with patients taking placebo. Read more here.